体育博彩

Ivonescimab Receives NMPA Approval for First-Line Treatment of PD-L1-Positive NSCLC, Based on Breakthrough Head to Head Phase III Trial Demonstrating Superior Efficacy Over Pembrolizumab
2025-04-26
Ivonescimab Receives NMPA Approval for First-Line Treatment of PD-L1-Positive NSCLC, Based on Breakthrough Head to Head Phase III Trial Demonstrating Superior Efficacy Over Pembrolizumab
Akeso Announces FDA Approval for Penpulimab-kcqx in Two BLA Indications for Comprehensive Treatment of Advanced Nasopharyngeal Carcinoma
2025-04-25
Akeso Announces FDA Approval for Penpulimab-kcqx in Two BLA Indications for Comprehensive Treatment of Advanced Nasopharyngeal Carcinoma
Ivonescimab in Combination with Chemotherapy Demonstrates Statistically Significant and Strongly Positive Results in First-Line Treatment of Squamous Non-Small Cell Lung Cancer (sq-NSCLC) vs. Tislelizumab in Combination with Chemotherapy  
2025-04-23
Ivonescimab in Combination with Chemotherapy Demonstrates Statistically Significant and Strongly Positive Results in First-Line Treatment of Squamous Non-Small Cell Lung Cancer (sq-NSCLC) vs. Tislelizumab in Combination with Chemotherapy  
Akeso’s Ebdarokimab ( IL - 12/IL - 23 Dual - Targeted Monoclonal Antibody) Approved in China for Moderate - to - Severe Plaque Psoriasis
2025-04-18
Akeso’s Ebdarokimab ( IL - 12/IL - 23 Dual - Targeted Monoclonal Antibody) Approved in China for Moderate - to - Severe Plaque Psoriasis
Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies
2025-03-31
Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies
Akeso’s Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer: Data Published at the 2025 SGO Annual Meeting  
2025-03-21
Akeso’s Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer: Data Published at the 2025 SGO Annual Meeting  
Akeso's Penpulimab Receives NMPA Approval for First-Line Treatment of Nasopharyngeal Cancer
2025-03-17
Akeso's Penpulimab Receives NMPA Approval for First-Line Treatment of Nasopharyngeal Cancer
Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet
2025-03-07
Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet
Akeso Announces Completion of Patient Enrollment in The Phase III Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma
2025-03-06
Akeso Announces Completion of Patient Enrollment in The Phase III Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma
Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy
2025-02-27
Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs
2025-02-25
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs
Akeso Announces IND Acceptance for AK139, a Bispecific Antibody Targeting IL-4Rα and ST2 for Respiratory and Skin Diseases
2025-02-14
Akeso Announces IND Acceptance for AK139, a Bispecific Antibody Targeting IL-4Rα and ST2 for Respiratory and Skin Diseases
沙巴体育 菠菜网平台大全 十大网络彩票平台大全 电竞菠菜 威尼斯人网上赌场